Comparing glucose monitors and a blood sugar test for diabetes in cystic fibrosis
Compares a wearable glucose monitor with a standard test for diabetes in cystic fibrosis.
Plain-language title generated from the registry record
Registry title: Continuous Glucose Monitoring and OGTT Screen for Cystic Fibrosis Related Diabetes in Cystic Fibrosis
Key facts
- Where
- Milwaukee, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cystic fibrosis who have normal or impaired glucose tolerance on a 2024 OGTT. It compares a continuous glucose monitor with the OGTT for diabetes screening.
- Age
- 18 years and older (adults)
- Sex
- All sexes can join.
- Disease stage
- Adults with cystic fibrosis and normal or impaired glucose tolerance on an OGTT completed in 2024. Not diagnosed with cystic fibrosis related diabetes (CFRD) on diabetes-causing medicines.
- Earlier treatment
- People with CFRD who are treated with diabetogenic medications cannot join. People who had a transplant cannot join.
- Biomarker or test result
- Normal glucose tolerance or impaired glucose tolerance on an OGTT done in 2024.
Main reasons for not taking part
- Diagnosed with CFRD and treated with diabetogenic medications
- Had a transplant
- Pregnancy
- Did not wear the CGM for the full 10 days
Read by machine on 9 November 2026.
Where in United States
- The Medical College of WisconsinMilwaukee, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical College of Wisconsin
- Trial code
- NCT06560463
- Record updated
- 31 July 2026
- Original description
Cystic Fibrosis (CF) related diabetes (CFRD) is a unique form of diabetes mellitus, different from type 1 diabetes and type 2 diabetes. The diagnosis of CFRD is associated with a decline in pulmonary function, decreased nutritional status, and increased mortality. CFRD is extremely common in people with CF, occurring in approximately 40-50% of adults with CF. Impaired glucose tolerance or dysglycemia is also very common in CF. It is standard of care to screen for CFRD annually from the age of 10 years with a two-hour Oral Glucose Tolerance Test (OGTT) with 75 g dextrose. The gold standard screening for CFRD is the OGTT which is problematic as it is time consuming for patient and staff and adherence to annual screening is low among CF centers.Read full original descriptionShow less
Comparison of Continous Glucose Monitor and OGTT as a Screen for Cystic Fibrosis Related Diabetes and Impaired Glucose Tolerance
Cystic Fibrosis (CF) related diabetes (CFRD) is a unique form of diabetes mellitus, different from type 1 diabetes and type 2 diabetes. The diagnosis of CFRD is associated with a decline in pulmonary function, decreased nutritional status, and increased mortality. CFRD is extremely common in people with CF, occurring in approximately 40-50% of adults with CF. Impaired glucose tolerance or dysglycemia is also very common in CF. It is standard of care to screen for CFRD annually from the age of 10 years with a two-hour Oral Glucose Tolerance Test (OGTT) with 75 g dextrose. The gold standard screening for CFRD is the OGTT which is problematic as it is time consuming for patient and staff and adherence to annual screening is low among CF centers.
Survival has improved dramatically with the advent of CFTR modulators and it is presumed that the incidence of CFRD will increase with increased life expectancy. The Cystic Fibrosis Foundation (CFF) has developed the oldest disease specific patient registry, consisting of approximately 35000 patients, so there is vast historical information available on individual patients and larger datasets on the CF community as a whole. Based on the 2021 CFF patient registry data, the current life expectancy for CF patients born between 2017 and 2021 is 53 years - a 15 year increase from a decade ago.
Inclusion: An adult patient, diagnosed with CF, established with Froedtert Multidisciplinary CF Clinic; Normal glucose tolerance or impaired glucose tolerance per OGTT completed in 2024; At healthy baseline status at time of CGM wear and OGTT.
Exclusion: Diagnosed with CFRD and treating with diabetogenic medications; s/p transplant; failure to wear CGM for entirety of 10 days; pregnancy.